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Carbonic anhydrases (CAs) are enzymes that catalyse the reversible hydration of CO
2
to bicarbonate. CA XII is considered a
potential biomarker of tumor cells and a promising target for specific therapies. The aim of the current study was to develop
new monoclonal antibodies (MAbs) against human recombinant CA XII and evaluate their diagnostic potential. An extracellular
catalytic domain of human CAXII was expressed in E. coli and used as an immunogen. Seven stable hybridoma cell lines producing
high-affinity IgG antibodies against human CA XII were generated. The majority of MAbs were highly specific to CA XII and
did not cross-react with human recombinant CA I, CA II, CA VII, and CA XIII. In order to demonstrate the diagnostic value
of the MAbs, they were employed for the immunohistochemistry analysis of CA XII expression in tissues. Two MAbs (15A4
and 4A6) demonstrated a strong and specific immunostaining of CA XII in human tissue specimens. Flow cytometry analysis
of 5 human tumor cell lines with the MAb 15A4 revealed its immunoreactivity with cellular CA XII. In conclusion, the MAbs
raised against recombinant catalytic domain of CA XII recognize cellular CA XII and represent a promising diagnostic tool for the
immunodetection of CA XII-expressing cells.
1. Introduction
The 𝛼-carbonic anhydrases (𝛼-CAs, EC 4.2.1.1) belong to
metalloenzymes that catalyse the reversible hydration of
carbon dioxide to bicarbonate (H
2
O + CO
2
↔ H+ +
HCO
3
−). So far, 15 different human CAs are identified that
differ in their enzymatic properties, subcellular localization,
and tissue distribution. Enzymatically active human CAs
are either cytosolic (CA I, CA II, CA III, CA VII, and CA
XIII), membrane bound (CA IV, CA IX, CA XII, and CA
XIV), mitochondrial (CA VA, and CA VB), or secretory (CA
VI). CAs are expressed in various cells and tissues such as
erythrocytes, gastrointestinal tract, reproductive tract, the
nervous system, kidney, lung, skin, eye, andmuscle [1–6].The
most important function of CAs is the transport of CO
2
in
various metabolizing tissues. CAs are also involved in other
physiological functions: pH regulation, ion transport, bone
resorption and secretion of gastric juice, cerebrospinal fluid,
and pancreatic juice [4].
Recent studies indicate that at least two of CA trans-
membrane isozymes—CA IX and XII—are associated with
human cancers. CA IX is a well-recognized tumor marker as
it is overexpressed in many types of tumors and is found in
only a few normal tissues [2]. There are increasing evidences
on the potential of CA XII as a new tumor marker. CA XII
is a transmembrane protein with an extracellular catalytic
domain. CA XII overexpression has been demonstrated in
human renal cell carcinoma [7] as well as in brain, colorectal,
breast, gastrointestinal, ovarian, and pancreatic cancers [6].
CA XII is also expressed in the normal human kidney, colon,
lung, brain, prostate, ovary, and testis [1, 8].
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The expression of CA IX and CA XII is induced
under hypoxic conditions through hypoxia inducible factor-
1. Hypoxia and consequent acidosis of tumor microenviron-
ment are principal features of many types of solid cancers.
Both CA IX and CA XII promote tumor growth and survival
through pH maintenance [6, 8–10]. Recent studies suggest
that the functions of CA IX and CA XII related to tumor
growth and metastasis, as well as their membrane-associated
localization, make these enzymes promising targets for spe-
cific therapies. Sulfonamides represent the main group of
the specific CA chemical inhibitors [11, 12]. Two monoclonal
antibodies (MAbs) against CA IX were generated as specific
immunological tools for clinical detection and therapy. Their
diagnostic value has been confirmed by immunohistochem-
istry and radiolabeled monoclonal antibody imaging [9].
Recently, the importance of CA XII as a serodiagnostic
marker for lung cancer has been demonstrated [13].TheMAb
6A10 raised against CA XII expressed in lung cancer cells has
been shown to inhibit CA XII enzymatic activity and tumor
growth in vitro [14].
The aim of the current study was to develop new
monoclonal antibodies (MAbs) against human recombinant
CA XII and evaluate their diagnostic potential. We have
demonstrated that the MAbs raised against recombinant
catalytic domain of CA XII recognize cellular CA XII and are
valuable reagents for its immunodetection in human tumor
tissue specimens.
2. Materials and Methods
2.1. Production of Recombinant Carbonic Anhydrases.
Recombinant extracellular domain of human CA XII
spanning amino acid (aa) residues from 30 to 291 was
expressed in E. coli cells and purified as described previously
[15]. In brief, E. coli Rosetta (DE3) strain cells (Novagen,
Germany) were transformed with recombinant expression
vector pET21a-CA XII. Transformants were cultured
in Luria-Bertani (LB) medium, containing 100 𝜇g/mL
ampicillin and 34 𝜇g/mL chloramphenicol and grown at
37∘C and 220 rpm for 16 h. The expression of CA XII was
induced with 1mM isopropyl b-D-thiogalactoside (IPTG)
and in the presence of 0.5mMZnSO
4
.The culture was grown
for 4 h at 30∘C and 220 rpm. The cells were harvested, mixed
with lysis buffer (20mM Hepes, 0.1% Triton X-100, 0.15M
NaCl, and 1mMPMSF; pH 8.5), and disrupted by sonication.
The soluble protein fraction was purified using a CA-affinity
column containing p-(aminomethyl)benzenesulfonamide
agarose (Sigma-Aldrich, St. Louis, USA). Eluted CA XII
protein was dialyzed against a storage buffer containing
10mM Hepes (pH 7.5) and 50mM NaCl. To test the
specificity of the MAbs to glycosylated form of CA XII, the
recombinant extracellular domain of human CA XII was
expressed in human cell line HEK293. For this purpose,
expression plasmid based on pCEP4dS vector designed
for the secretion of recombinant mammalian proteins was
constructed. The pCEP4dS vector for insertion of CA XII
gene was constructed from the pCEP4 vector (Invitrogen,
Life Technologies) by making two modifications. First, the
vector size was reduced by the deletion of 1990 base pair
fragment between the restriction sites of SalI (9953) andNruI
(7963). Second, the secretion signal was introduced into a
multiple cloning sites. Two complementary single stranded
oligonucleotides, containing the secretion signal from the
V-J2-C region of murine Ig kappa chain were chemically
synthesized and annealed. The resultant double stranded
oligonucleotide was digested at the 5󸀠 and 3󸀠 ends with KpnI
and HindIII, respectively, and ligated into the vector cut with
the same enzymes. For the expression of mammalian CAXII,
the pCEP4dS-CAXII plasmid was constructed. The DNA
fragment, corresponding to the catalytic domain of CA XII
(amino acids 30 to 291), was cut out from the pET21a-CAXII
plasmid [15] with NdeI and BamHI restriction endonucleases
and ligated into the pCEP4dS vector, digested with HindIII
and BamHI. Recessed 3󸀠-termini resulting from the digestion
with NdeI and HindIII were filled in by Klenow fragment
before the ligation. Because of the linker located between
the secretion signal and the coding sequence of CA XII,
the expressed CA XII protein has additional 8 amino acids
(DAAHMKLM) at the N terminus.
Expression of CA XII was carried out using the FreeStyle
Max 293 expression system (Invitrogen, Life Technolo-
gies). FreeStyle 293-F suspension cell culture was main-
tained in 125–500mL Erlenmeyer flasks containing 30–
120mL of FreeStyle medium in a 37∘C incubator with a
humidified atmosphere of 8% CO
2
, on an orbital shaker
platform rotating at 135 rpm. FreeStyle cells were tran-
siently transfected with the purified pCEP4dS-CAXII plas-
mid according to manufacturer’s recommendations. Four
days later, the cell culture was centrifuged at 6000 g for
20min and the secreted CA XII protein was purified from
the supernatant using a CA-affinity column containing p-
(aminomethyl)benzenesulfonamide agarose (Sigma-Life Sci-
ence Aldrich). The eluted CA XII protein was dialyzed into a
storage buffer containing 10mM Hepes (pH 7.5) and 50mM
NaCl and stored at −80∘C.
Recombinants CA I, CA II, CA VII, and CA XIII were
expressed in E. coli and purified as described previously [16].
2.2. Production of GST-Fused CA XII Segments for Epitope
Mapping. DNA fragments encoding three overlapping seg-
ments of CA XII, number 1 (aa 27–130), number 2 (aa 111–
210), andnumber 3 (184–290), were amplified from full length
CAXII DNAby polymerase chain reaction (PCR) and cloned
into bacterial expression vector pGex4T2. Three pairs of
primers with restriction endonuclease recognition sites, start
and stop codons, were used in PCR (Table 1).
CA XII segments fused to glutathione-S-transferase
(GST) were expressed in E. coli BL21 (DE3) strain (Novagen).
Transformed cells were grown in LB medium, containing
100 𝜇g/mL ampicillin at 37∘C and 220 rpm for 16 h. The
saturated culture was diluted (1 : 50) in fresh LB medium,
containing 100 𝜇g/mL ampicillin and 0.04 𝜇M ZnSO
4
and
grown to the optical density (OD) at 600 nm OD
600
≈0.8.
The expression of GST-fused CA XII segments was induced
with 1mM IPTG and in the presence of 0.4mM ZnSO
4
. The
culture was grown for 4 h at 30∘C and 220 rpm. The cells
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Table 1: PCR primers used to produce three overlapping segments of CA XII.
Segment number Segment sequence PCR primer sequences∗ Restriction endonuclease
#1 Val 27-Gly130 5
󸀠 CCCGGGATCCGTGAACGGTTCCAAG 3󸀠 BamHI
5󸀠 ACGGCGGCCGCTTAGCCGTGCGGGTCATT 3󸀠 NotI
#2 Ser111-Leu210 5
󸀠 GGGCGGATCCTCTCGCTACAGTGCC 3󸀠 BamHI
5󸀠 GTCCTCTCGAGTTACAGCTCTTCAATGTTG 3󸀠 XhoI
#3 Asp184-Ser290 5
󸀠 TCCGGGATCCGACAAGATCTTCAGTC 3󸀠 BamHI
5󸀠 AGACCTCGAGTTAGGAGAAGGAGGTGTATAC 3󸀠 XhoI
∗Restriction endonuclease recognition sites are underlined.
were harvested, mixed with lysis buffer (20mM Hepes, 0.1%
Triton X-100, 0.15M NaCl, (pH 8.5), and 1mM PMSF), and
disrupted by sonication. The expression levels of GST-fusion
proteins (GST-segment number 1, 37.44 kDa; GST-segment
number 2, 37.42 kDa; GST-segment number 3, 38.92 kDa)
in the respective lysates of transformed E. coli cells were
evaluated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE).
2.3. Generation of Monoclonal Antibodies. Three 6–8-week-
old female BALB/c mice (obtained from a breeding colony at
the Department of Immunology of the Center for Innovative
Medicine, Vilnius, Lithuania) were immunized by a subcu-
taneous injection of 50 𝜇g of recombinant CA XII. For an
initial immunization, the antigen was emulsified in complete
Freund adjuvant (Sigma). Subsequent immunizations at days
28 and 56 were performed without an adjuvant, with the
antigen dissolved in PBS, respectively. Antiserawere collected
two weeks after each injection and tested for the presence of
CA XII-specific antibodies by an indirect ELISA. The mouse
with the highest antibody titer was boosted subcutaneously
with 50𝜇g of CA XII dissolved in PBS 3 days before the
cell fusion. Hybridomas were generated as described by
Kohler and Milstein [17]. Mouse splenocytes were fused
with Sp2/0-Ag 14 mouse myeloma cells using polyethylene
glycol 4000 (PEG, Roth). Hybrid cells were selected in
growth medium supplemented with HAT (hypoxanthine,
aminopterin, and thymidine) (50x HAT media supplement,
Sigma-Aldrich). Culture supernatants from wells with viable
cloneswere screened by an indirect ELISAusing recombinant
CA XII protein. Stable hybridoma clones secreting CA XII-
specific antibodies were obtained after two cloning cycles
by a limiting dilution assay. Hybridoma cells were grown
in complete Dulbecco’s modified Eagle’s medium (DMEM,
Biochrom) supplemented with 15% fetal bovine serum (FBS,
Biochrom), 2mM L-glutamine, and 200 𝜇g/mL gentamicin.
All procedures involving experimental mice were performed
under controlled laboratory conditions in strict accordance
with the Lithuanian and European legislation.
2.4. Indirect ELISA. The specificities of mouse antisera and
hybridoma supernatants were investigated by an indirect
ELISA. Recombinant CA XII diluted in coating buffer
(0.05M sodiumcarbonate salt, pH9.6) to 5𝜇g/mLwas coated
on plates (Nerbe) at 50 𝜇L aliquot per well and incubated at
4∘C overnight. The coated wells were blocked with 150 𝜇L
of 1% BSA solution in PBS for 1 hour at room temperature
(RT). Plates were washed two times with PBS-Tween buffer
(0.1% Tween 20 in PBS). Antiserum samples or hybridoma
growth medium were diluted in PBS-Tween buffer, added to
the wells (50 𝜇L/well), and incubated for 1 hour at RT. The
plates were rinsed 5 times with PBS-Tween buffer and then
incubated with 50𝜇L of goat anti-mouse IgG conjugated to
horseradish peroxidase (HRP) (Bio-Rad) diluted 1 : 5000 in
PBS-Tween buffer for 1 hour at RT. The plates were washed
5 times with PBS-Tween buffer. Peroxidase activity was
detected using 50 𝜇L of ready-to-use TMB substrate (Sigma)
per well. After 10min of incubation at RT, the reaction was
stopped by adding 25 𝜇L aliquot per well of 10% H
2
SO
4
. The
optical density (OD)wasmeasured at 450 nm (reference filter
620 nm) using microplate reader (Tecan, Gro¨dig, Austria).
The isotypes of the MAbs were determined by ELISA
using the monoclonal antibody isotyping kit (Thermo Fisher
Scientific, Vilnius, Lithuania) according to themanufacturer’s
protocol.
2.5. Determination of the Apparent Dissociation Constant
(𝐾
𝑑
). The apparent dissociation constants (Kd) of the MAbs
were determined by an indirect ELISA as described previ-
ously [18]. Briefly, the MAbs were prepared in concentrations
ranging from 1.9 × 10−13M to 3.3 × 10−8M and incubated
in the microtiter plates coated with recombinant CA XII.
The plates were then incubated with HRP-labelled anti-
mouse IgG (Bio-Rad) and developed with TMB substrate.
The apparent Kd was calculated from a titration curve and
defined as a molar concentration of the MAbs corresponding
to the midpoint between maximum OD
450
value and the
background.
2.6. SodiumDodecyl Sulfate-Polyacrylamide Gel Electrophore-
sis. Before sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE), protein samples were added to the
Line Marker Reducing sample buffer (Thermo Scientific)
and boiled for 5min. Protein samples (1 𝜇g per lane) were
separated by electrophoresis on 12% polyacrylamide gel. The
gels were visualized by staining with Coomassie brilliant blue
(Sigma).
2.7. Immunoblotting. After SDS-PAGE, proteins were trans-
ferred to a polyvinylidene difluoride (PVDF) membrane
(Roth). The membranes were blocked with 5% milk powder
in PBS for 1 h at RT. The membranes were incubated with
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undiluted hybridoma supernatants for 1 h at RT, followed
by incubation with goat anti-mouse IgG conjugated to
horseradish peroxidase (HRP) (Bio-Rad) diluted 1 : 4000
in PBS-Tween buffer. The enzymatic reaction was devel-
oped using tetramethylbenzidine (TMB) ready-to-use chro-
mogenic substrate (Sigma).
2.8. Flow Cytometry Analysis. The reactivities of the MAbs
with cellular CA XII were investigated by flow cytometry
using 5 human cell lines: A-498 (human kidney carcinoma),
U-87 (human primary glioblastoma), A-549 (human lung
adenocarcinoma), HeLa (human cervical carcinoma), and
CaSki (human cervical carcinoma) (ATCC, Manassas, VA,
USA). As a negative control, Chinese hamster ovary (CHO)
cells were used. Cells were cultivated in RPMI-1640 growth
medium (Biochrom, Berlin, Germany) supplemented with
10% fetal bovine serum (Biochrom), 2mM L-glutamine, and
200𝜇g/mL gentamicin in humidified atmosphere at 37∘C
and 5% CO
2
to approximately 70% confluence. Harvested
cells (106 cells per test) were fixed using a buffer containing
paraformaldehyde, washed with BD Perm/Wash buffer (BD
Biosciences), and incubatedwith hybridoma growthmedium
at 4∘C for 30min. As a negative control, irrelevant MAbs of
IgG1 and IgG2a isotypes were used. Binding of the antibodies
was determined using FITC-conjugated goat anti-mouse IgG
(BD Pharmingen, Franklin Lakes, USA) and measured by
standard flow cytometry (FACS) with CyFlowRspace flow
cytometer (Partec, Muenster, Germany). Not less than 20000
events per test were evaluated with FloMax 2.7 software.
2.9. Immunohistochemistry Analysis. Immunohistochemical
staining was performed on formalin-fixed and paraffin-
embedded samples of colon adenoma, colon carcinoma, renal
carcinoma and normal colon, and kidney tissues at the
Institute of Biomedical Technology, University of Tampere
(Tampere, Finland). Tissue specimens were collected and
tested for CA XII expression as described previously [19].
Tissue sections (approximately 5 𝜇m thick) were stained
using an automated Lab Vision Autostainer 480 (LabVision
Corporation, Fremont, CA, USA) and Power Vision Poly-
HRP Immunohistochemistry kit (ImmunoVision Technolo-
gies, Burlingame, CA, USA) according to the manufacturer’s
protocol. Samples were deparaffinized in xylene and rehy-
drated in graded alcohols. Tissue sections were incubated
in 3% H
2
O
2
for 5min and blocked with cow colostrum
diluted 1 : 2 in Tris-buffered saline containing 0.05% Tween-
20 for 30min at RT. Slides were incubated with the MAbs
for 30min. After rinsing in wash buffer for 35min, samples
were incubated in poly-HRP-conjugated anti-rabbit/mouse
IgG (ImmunoVision Technologies) for 30min. Slides were
visualized using 3,3-o-diaminobenzidine tetrahydrochloride
(DAB) ready-to use solution (ImmunoVision Technologies).
3. Results
3.1. Generation of Hybridomas Producing MAbs against
Recombinant CA XII. In order to generate hybridomas,
BALB/c mice were immunized with recombinant CA XII
expressed in E. coli and purified by affinity chromatogra-
phy. Recombinant CA XII represents the N-terminal cat-
alytic domain (aa 30–291) of CA XII and lacks the signal,
transmembrane, and cytoplasmic domains. To evaluate the
immunogenicity of the recombinant CA XII, antiserum
specimens were collected after each injection and tested for
the presence of CA XII-specific antibodies by an indirect
ELISA. After 3 immunizations, the titers of CA XII-specific
IgG antibodies in the sera of immunized mice ranged from
1 : 9000 to 1 : 21000 (data not shown). Thus, recombinant CA
XII was immunogenic in mice. Spleen cells of the mouse
with the highest antibody titer were fused with mouse
myeloma cells following standard procedures. At the 12th
day after cell fusion, hybrid clones secreting CA XII-specific
antibodies were screened by an indirect ELISA on plates
coated with the recombinant CAXII. Seven stable hybridoma
cell lines producing CA XII-specific MAbs of IgG isotype
were generated (Table 2). Six out of 7 MAbs were of IgG1
subtype; one MAb (clone 15A4) was of IgG2a subtype. The
hybridomas were cultivated in culture and the supernatants
were collected for further characterization of the MAbs.
3.2. Specificity and Affinity of the MAbs. All MAbs were
reactive in ELISA with the recombinant E. coli-expressed CA
XII (data not shown). To test the reactivity of the MAbs
with SDS-denatured antigen, the purified CA XII protein
and crude lysate of E. coli transformed with pET21a-CA XII
vector were denatured by boiling in sample buffer (Thermo
Fisher Scientific) containing SDS and 2-mercaptoethanol and
subjected to protein electrophoresis and immunoblotting.
All MAbs specifically recognized protein band of 31 kDa,
which corresponded to recombinant CA XII (Figure 1, lane
1) and did not cross-react with other proteins of E. coli lysates
(Figure 1, lane 2). Thus, all MAbs were reactive with SDS-
denatured recombinant CA XII (Table 2).
As theMAbs were raised against E. coli-expressed recom-
binant CA XII that did not undergo posttranslational mod-
ifications, the ability of the MAbs to recognize glycosylated
form of CA XII was evaluated. For this purpose, the reac-
tivities of the MAbs with recombinant CA XII expressed in
humanHEK 293 cells were tested both by ELISA andWestern
blot. The MAbs differed in their capability to recognize
glycosylated CA XII expressed in mammalian cells. MAbs
4A6, 9A8, and 15A4 showed a strong reactivity with the
recombinant glycosylatedCAXII both byELISA andWestern
blot (Figure 1, lane 3, Table 2). In contrast,MAbs 1D5 and 5D2
were nonreactive with CA XII expressed in mammalian cells
(Table 2). MAbs 8C9 and 13F5 showed a moderate reactivity
with CA XII expressed in mammalian cells (Figure 1, lane 3,
Table 2).
To investigate the cross-reactivities of the MAbs with CA
isoforms other than XII, the previously purified CAs were
used [15].The analysis ofMAb reactivities both by ELISA and
Western blot revealed that 6 MAbs reacted exclusively with
the recombinant CAXII and did not show any reactivity with
recombinants CA I, CA II, CA VII, and CA XIII (Table 2).
Only the MAb 13F5 showed a weak cross-reactivity with CA
II and CA VII in ELISA but not in Western blot (Table 2).
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Figure 1: Reactivity of the MAbs with denatured recombinant CA XII expressed in E. coli and mammalian cells. Upper-leftmost panel: SDS-
PAGE; remaining panels: immunoblot withMAbs 1D5, 4A6, 5D2, 8C9, 9A8, 13F5, and 15A4. LineM: prestainedMWmarkers (Thermo Fisher
Scientific, Vilnius); line 1: purified recombinant CA XII proteinexpressed in E. coli; line 2: lysate of E. coli Rosetta (DE3) strain cells; line 3:
purified recombinant CA XII protein expressed in mammalian cells.
To determine the affinity of the MAbs, their apparent 𝐾
𝑑
values were measured by an indirect ELISA. The 𝐾
𝑑
values
of the MAbs calculated from three experiments ranged from
1.07 × 10
−9M to 6.17 × 10−10M, indicating high-affinity
binding (Table 2).
3.3. Localization of MAb Epitopes. To identify the epitopes
of recombinant CA XII recognized by the MAbs, three
partially overlapping GST-fused fragments of CA XII were
constructed: fragment number 1 (aa 27–130), fragment num-
ber 2 (aa 110–210), and fragment number 3 (aa 184–290).
Schematic representation of GST-fused CA XII fragments is
shown in Figure 2.
GST-fused fragments of CA XII were expressed in E.
coli BL21 (DE3) strain. Expression levels of GST-fused CA
XII fragments in E. coli lysates were analysed by SDS-
PAGE andWestern blot using commercial antibodies against
GST (Figure 3). All fragments were efficiently expressed in
transformed E. coli cells. The reactivities of the MAbs with
GST-fused CA XII fragments were investigated by Western
blot using lysates of transformed E. coli cells expressing the
respective fragments. MAbs 1D5, 4A6, and 5D2 recognized
fragment number 1 that represents the N-terminal region of
CA XII (aa 27–130). As the MAbs 1D5, 4A6, and 5D2 were
reactive with the whole recombinant catalytic domain of CA
XII (aa 30–291) and did not recognize fragment number 2 (aa
111–210), the epitopes for theseMAbswere located between aa
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Figure 2: Schematic representation of GST-fused CA XII fragments used for epitope mapping. Wt CA XII: full length CA XII. Recombinant
CA XII-E. coli-expressed extracellular catalytic domain of CA XII used for the generation and characterization of MAbs.
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Figure 3: Analysis of the expression of GST-fused CA XII fragments in E. coli lysates. (a) SDS-PAGE. (b) Western blot with anti-GST MAbs
(Thermo Scientific): lane M: prestained MWmarkers (Thermo Scientific); lane 1: purified recombinant CA XII protein; lanes 2–4: lysates of
transformed E. coli cells expressing CAXII fragments number 1 (lane 2), number 2 (lane 3), and number 3 (lane 4); line 5: lysate of transformed
E. coli cells expressing GST. Arrow (←) indicates GST-fused CA XII fragments.
30 and 110 of CA XII. MAbs 8C9 and 13F5 reacted exclusively
with fragment number 3 that represents C-terminal region
of CA XII (aa 184–290). As the MAbs 8C9 and 13F5 did not
recognize an overlapping fragment number 2 (aa 111–210), the
epitopes for theseMAbs were located between aa 210 and 290
of CA XII. MAbs 9A8 and 15A4 recognized both fragment
numbers 2 and 3. It was concluded that their epitopes are
located between aa 184 and 210, as this is an overlapping
sequence of both fragment numbers 2 and 3. Summarized
data on MAb reactivities with GST-fused CA XII fragments
are presented in Table 3.
3.4. The Reactivities of the MAbs with the Cellular CA XII
by Flow Cytometry. To investigate the reactivities of the
MAbs with the cellular full-length CA XII, we have used
human cancer cell lines A-498 (human kidney carcinoma),
U-87 (human primary glioblastoma), A-549 (human lung
adenocarcinoma), HeLa (human cervical carcinoma), and
CaSki (human cervical carcinoma) with previously reported
different expression levels of CA XII [13, 20]. As a negative
control, Chinese hamster ovary (CHO) cells were used. The
cells were cultivated under normoxic conditions, then treated
with the MAbs and analysed by flow cytometry. The MAbs
differed in their capacity to recognize the cellular CA XII
in human cancer cell lines. The MAb 15A4 showed a strong
specific immunostaining of A-498, U-87, A-549, CaSki, and
HeLa cells and had no reaction with CHO cells used a as
a negative control (Figure 4(a)). In contrast, no reactivity of
the MAbs 1D5, 4A6, 5D2, and 9A8 with these cell lines was
observed (Figure 4(b)).The MAbs 8C9 and 13F5, however,
were reactive both with human cell lines and CHO cells (data
not shown), indicating nonspecific staining.
3.5. The Reactivities of the MAbs with the Cellular CA XII
by Immunohistochemistry. Immunohistochemistry analysis
(IHC) was used to investigate the reactivities of the MAbs
with the cellular full-length CA XII protein on formalin-
fixed and paraffin-embedded samples of colon adenoma,
colon carcinoma, renal carcinoma, and normal colon and
kidney tissues. Two MAbs, clones 4A6 and 15A4, showed
specific immunostaining of renal carcinoma, colon adenoma,
and colon carcinoma specimens and did not show any
8 BioMed Research International
80
60
40
20
0
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4 10
0
10
1
10
2
10
3
10
4
C
ou
nt
C
ou
nt
C
ou
nt
C
ou
nt
C
ou
nt
C
ou
nt
FITC
FITC FITC FITC
FITCFITC
120
90
60
30
0
88
66
44
22
0
98
74
49
25
0
112
84
56
28
0
115
86
58
29
0
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
U-87, 15A4 A-549, 15A4 A-498, 15A4
CHO, 15A4CaSki, 15A4HeLa, 15A4
(a)
C
ou
nt
C
ou
nt
C
ou
nt
FITC FITC FITC
113
85
57
28
0
103
77
52
26
0
121
91
61
30
0
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
410
0
10
1
10
2
10
3
10
4
A-498, 1D5 CaSki, 1D5 CHO, 1D5
(b)
Figure 4: Flow-cytometry analysis ofU-87, A-549, A-498,HeLa, andCaSki cell lines immunostainedwith theMAbs: (a) 15A4 (IgG2a subtype)
(black line); (b) 1D5 (IgG2a subtype) (black line); irrelevant MAbs of IgG1 or IgG2a subtypes were used as negative control (gray line).
Table 3: The reactivity of the MAbs with GST-fused CA XII fragments and predicted localization of MAb epitopes.
MAb clone CA XII protein fragments Predicted localization of MAb epitopes
#1 (aa 27–130) #2 (aa 111–210) #3 (aa 184–290)
1D5 + − − aa 30–110
4A6 + − − aa 30–110
5D2 + − − aa 30–110
8C9 − − + aa 210–290
9A8 − + + aa 184–210
13F5 − − + aa 210–290
15A4 − + + aa 184–210
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(a) (b)
(c) (d)
(e) (f)
Figure 5: Immunostaining of colon adenoma (a), normal colon (b), normal kidney ((d), (f)), and renal carcinoma ((c), (e)) specimens for
CAXII expression using newly producedmAbs 15A4 ((a)–(d)) and 4A6 ((e), (f)). MAb clone 15A4 hybridoma supernatant was diluted 1 : 100;
4A6-1 : 10. Original magnifications ×400.
unspecific background staining of the respective normal
tissues (Figure 5).TheMAb4A6was reactive in IHCat higher
concentrations (dilution of hybridoma supernatant 1 : 10,
Figures 5(e) and 5(f)) as compared to theMAb 15A4 (dilution
of hybridoma supernatant 1 : 100, Figures 5(a)–5(d)), which
is explained by different affinities of the MAbs: 𝐾
𝑑
were
1.07 × 10
−9 and 2.02 × 10−10, respectively. Other MAbs did
not show any specific immunostaining of tissue specimens
(data not shown). Thus, the IHC results demonstrate the
potential of the MAbs 4A6 and 15A4 as specific reagents
for the immunodetection of CA XII in formalin-fixed and
paraffin-embedded tissue specimens.
4. Discussion
CA XII is a single-pass transmembrane protein with an
extracellular catalytic domain [1]. Based on its role in tumor
progression, this enzyme is considered to be a useful diag-
nostic and prognostic biomarker for different tumors [6].
However, the data on CA XII distribution in normal and
tumor tissues are still incomplete. Investigation of CA XII
expression in different cell types might be promoted by the
availability of highly specific and well-characterized MAbs.
To generate MAbs against membrane-bound proteins, such
as carbonic anhydrases, immunizations with intact cells,
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or cell lysates containing target protein, has been proven
useful. The first MAb against CA IX was generated after
immunization of mice with human renal cell carcinoma
cells [21]. The MAbs raised against cellular CA IX have
been employed for the identification of CA IX in renal cell
carcinoma and other tumor cells, as well as targeting tumor
cells by an enhanced internalization of antibody-bound CA
IX [9]. Based on these investigations and other studies
confirming the importance of CA IX in tumor development,
chimeric MAb G250 against CA IX has been generated and
evaluated in a clinical trial for tumor-specific therapy [22].
Recently, two research groups generated MAbs against CA
XII after immunization either with A549 cell lysate or live
cells, respectively [13, 14]. Selection of positive hybridomas
after immunization of rats with live A549 lung cancer cells
was performed by flow cytometry using intact A549 cells.The
MAb6A10 raised against cellular CAXIIwas shown to inhibit
CA XII enzymatic activity and growth of tumor cells in vitro
[14].
In the current study, we have applied another approach
to generate CA XII-specific MAbs. As an immunogen, we
have used the recombinant E. coli-expressed catalytic domain
of CA XII. Immunization with the recombinant antigen
was successful and resulted in a panel of CA XII-specific
MAbs that differed in their cross-reactivities with other CA
isoforms as well as their ability to recognize cellular CA XII
or mammalian cell-derived recombinant CA XII. Six out
of 7 newly developed MAbs were reactive exclusively with
CA XII and did not recognize other CA isoforms used in
this study: CA I, CA II, CA VII, and CA XIII. Five out of
7 MAbs were reactive with recombinant CA XII expressed
in HEK 293 cells, which differs from the E. coli-expressed
protein according to its glycosylation pattern. The reactivity
of the MAbs with glycosylated CA XII is in line with epitope
mapping data performedwithin the current study. According
to the UniProt database, glycosylation sites in CA XII are
located at Asn-28, Asn-80, and Asn-162 [23]. The MAbs 1D5
and 5D2, directed against N terminally located epitope (aa
30–110), did not recognize mammalian cell-derived CA XII,
while theMAb 15A4 directed against the aa 192–205 sequence
of CA XII not containing potential glycosylation sites was
strongly reactive with mammalian cell-derived recombinant
CA XII both by ELISA and Western blot. The ability of the
MAb 15A4 to recognize properly modified cellular CA XII
was also confirmed by flow cytometry as this MAb showed a
strong specific immunostaining ofA-498,U-87, A-549, CaSki,
and HeLa cells expressing CA XII. Moreover, the MAb 15A4
recognized cellular CA XII protein by IHC on formalin-fixed
and paraffin-embedded specimens of renal carcinoma, colon
adenoma, and colon carcinoma as well as normal kidney and
colon tissues. These data demonstrate the potential of the
MAb 15A4 as a highly specific reagent for studying CA XII
expression in tumor and normal tissues.
5. Conclusions
Our approach to use the recombinant E. coli-expressed
catalytic domain of CA XII as an immunogen was successful
and resulted in highly specificMAbs reactive with cellular CA
XII. The well-characterized MAbs, in particular clone 15A4,
represent a promising diagnostic tool for the immunodetec-
tion of CA XII in biological specimens.
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